U.S. markets closed

Immutep Limited (PRRUF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.36000.0000 (0.00%)
At close: 1:07PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3600
Open0.3565
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3600 - 0.3600
52 Week Range0.0900 - 0.8000
Volume2,600
Avg. Volume5,670
Market Cap238.413M
Beta (5Y Monthly)1.45
PE Ratio (TTM)N/A
EPS (TTM)-0.0440
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Immutep Quarterly Activities Report
    GlobeNewswire

    Immutep Quarterly Activities Report

    Immutep entered late-stage development in the newly validated LAG-3 spaceData from 1st line NSCLC and 2nd line HNSCC presented at ASCOEfti to be evaluated in new triple combination therapy trial and entered into a new collaboration with Merck KGaA for efti and bintrafusp alpha SYDNEY, AUSTRALIA, July 13, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and aut

  • Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
    GlobeNewswire

    Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC

    Sydney, July 06, 2021 (GLOBE NEWSWIRE) -- ASX/Media Release Regulatory steps completed with the competent authority (FDA) and institutional review board (IRB) approval received in the United States to commence TACTI-003Patient recruitment into the trial is expected to begin within this quarter with European and Australian sites expected to follow Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments

  • Immutep Shares Are Trading Higher On Green Signal To Start Efti Combo Trial In First-Line Head & Neck Cancer
    Benzinga

    Immutep Shares Are Trading Higher On Green Signal To Start Efti Combo Trial In First-Line Head & Neck Cancer

    Immutep Limited (NASDAQ: IMMP) has completed all the necessary steps with the FDA and has received institutional review board approval to commence its Phase 2b TACTI-003 trials in the U.S. Patient recruitment for the trial will begin in Q3 of 2021. It will evaluate the Company's lead product candidate, eftilagimod alpha (efti or IMP321), in combination with Merck Co & Inc's (NYSE: MRK) Keytruda (pembrolizumab) as first-line therapy in approximately 154 patients with Head and Neck Squamous Cell C